Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/leader-2021-000532 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacokinetics of Depemokimab Delivered by Safety Syringe Device or Autoinjector in Healthy Adults: A Phase I, Single-Dose Study.
Clin Pharmacol Drug Dev
January 2025
Clinical Research Unit, PPD, Austin, TX, USA.
Article Synopsis
- The study compared the bioavailability of the anti-interleukin-5 antibody depemokimab when delivered using a safety syringe device (SSD) versus an autoinjector (AI) in healthy adults.
- Both methods showed similar plasma concentration profiles and pharmacokinetic parameters, confirming that they are bioequivalent.
- Adverse events were minor and comparable between the two delivery methods, with headaches being the most common side effect, indicating both devices are safe for administering depemokimab.
Baseline Sex Differences in Pulmonary Arterial Hypertension Randomized Clinical Trials.
Ann Am Thorac Soc
January 2023
Department of Biostatistics, Epidemiology, and Informatics and.
Sex-based differences in pulmonary arterial hypertension (PAH) are known, but the contribution to disease measures is understudied. We examined whether sex was associated with baseline 6-minute-walk distance (6MWD), hemodynamics, and functional class. We conducted a secondary analysis of participant-level data from randomized clinical trials of investigational PAH therapies conducted between 1998 and 2014 and provided by the U.
View Article and Find Full Text PDFTerminal Digit Preference in Pulmonary Hypertension Endpoints.
Am J Respir Crit Care Med
June 2022
University of Pennsylvania Philadelphia, Pennsylvania.
BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis.
Chest
August 2022
Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. Electronic address:
Background: Obesity is increasingly prevalent in pulmonary arterial hypertension (PAH) but is associated with improved survival, creating an "obesity paradox" in PAH. It is unknown if the improved outcomes could be attributable to obese patients deriving a greater benefit from PAH therapies.
Research Question: Does BMI modify treatment effectiveness in PAH?
Study Design And Methods: Using individual participant data, a meta-analysis was conducted of phase III, randomized, placebo-controlled trials of treatments for PAH submitted for approval to the U.
Association of Pericardial Fat with Cardiac Structure, Function, and Mechanics: The Multi-Ethnic Study of Atherosclerosis.
J Am Soc Echocardiogr
June 2022
Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Electronic address:
Background: Pericardial fat has been associated with adverse cardiovascular outcomes through adiposity-associated inflammation and insulin resistance, which in turn are linked to cardiac dysfunction. We sought to evaluate the association between pericardial fat volume and cardiac structure and function in adults without baseline cardiovascular disease.
Methods: We analyzed data from the Multi-Ethnic Study of Atherosclerosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!